Abiopharma

🔍 Leproust Emily M. (Executive)

Company: Twist Bioscience Corp (TWST)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Sold 6,639 shares of Common Stock at $139.066 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 812,299.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Employee Stock Option (right to buy) at $5.95 per share (Derivative)
  Date: 2026-08-21 | Code: H | Expires: 2025-09-28 | Footnotes: F2
• Holds 0 shares of Employee Stock Option (right to buy) at $8.82 per share (Derivative)
  Date: 2026-08-21 | Code: H | Expires: 2027-09-28 | shares_owned_after: 75,439.00 | Footnotes: F3
• Holds 0 shares of Employee Stock Option (right to buy) at $26.66 per share (Derivative)
  Date: 2026-08-21 | Code: H | Expires: 2028-11-18 | shares_owned_after: 133,269.00 | Footnotes: F4
• Holds 0 shares of Employee Stock Option (right to buy) at $23.33 per share (Derivative)
  Date: 2026-08-21 | Code: H | Expires: 2029-10-23 | shares_owned_after: 131,290.00 | Footnotes: F5
• Holds 64,950 shares of Employee Stock Option (right to buy) at $67.85 per share (Derivative)
  Date: 2026-08-21 | Code: H | Expires: 2030-08-31 | Exercise: 2022-12-19 | shares_owned_after: 64,950.00 | Footnotes: F6

Footnotes:

• F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
• F2: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
• F3: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
• F4: 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
• F5: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
• F6: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.